Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
about
Poxvirus vectors as HIV/AIDS vaccines in humansMatrix and backstage: cellular substrates for viral vaccinesPre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow feverRecombinant Mycobacterium bovis BCG as an HIV vaccine vector.Human immunodeficiency virus vaccine trialsHIV-1 Vaccine Trials: Evolving Concepts and DesignsBalancing collective responsibility, individual opportunities and risks: a qualitative study on how police officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania.Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trialsProtection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes.Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses.High throughput T epitope mapping and vaccine developmentNovel directions in HIV-1 vaccines revealed from clinical trialsSafety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in miceDNA/MVA Vaccines for HIV/AIDSPrime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in miceSafety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersRegression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling PathwaysA phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infantsVaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructsVaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectorsDNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adultsModified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation.Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in miceDeletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase.Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments.Current progress of DNA vaccine studies in humans.Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.Recombinant lentogenic Newcastle disease virus expressing Ebola virus GP infects cells independently of exogenous trypsin and uses macropinocytosis as the major pathway for cell entry.Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors.MHC-I-restricted epitopes conserved among variola and other related orthopoxviruses are recognized by T cells 30 years after vaccination.
P2860
Q26995078-A9C8B049-2213-4431-9060-4A6F99E0D43FQ27025941-6D35D68F-C1D5-4258-8B3A-E5A11A82B0D8Q28740522-2F0F9F37-4BD9-41A7-9C77-54F7C3A81F92Q30387447-F8A1D9F6-73DF-4B40-8F6B-9363DFAE0B0AQ30424366-83481220-1598-4DB1-ACE3-AA48A3C5B69BQ30425520-8EE6D69D-CEBB-401F-BAAA-72BE8A4AAC63Q30983687-78B046B8-B727-42D4-A6FB-A656653EA999Q33303660-CFBA5345-EC78-4289-8272-59DB98C415C1Q33353872-A2369B47-82D7-4A37-8E50-177D543855F4Q33602820-9FE96337-5D6E-494A-ACFC-2F1231FFEC34Q33628719-7E935317-2353-4B3D-95D5-0F57580A8534Q33645528-85C43A76-3C8C-4A90-9FCA-1F1C91CAD137Q33875160-CF8DF8DC-EC9F-4969-A8B1-E82A6AD16844Q34428899-5E4A4EC9-0586-4835-B368-6FCD93C84890Q34492802-5DFE6EDB-A4E6-4B52-9668-02D1C89CA6ECQ34510430-F7397050-7792-4398-89E1-49C0DC308ABBQ34589611-EF8F453F-BE97-41AE-A587-9BFBC3DEB930Q34729962-E9A3C3A2-4E2B-4106-B1F1-345141EE2926Q34796206-B4925F68-BA90-4FCD-AD8E-5CDB1932FD37Q35036289-F174BB4F-23EA-4A5C-920B-F99DEFD3FA92Q35571248-2D47D4B1-2C0F-423E-AEC8-AD465FC04693Q35677724-3EEB1B21-F124-4941-9D89-216D77E0A7EAQ35751946-E174FAD4-6DBB-4510-A14C-57088F8224DDQ35914427-D6D07097-2E1F-4358-A37C-FD8F02C7C77EQ35940696-EAF9A916-74AA-4575-898D-119250AE7597Q35943471-BD9DAB32-7533-461B-968C-B88E7CC39170Q35947683-D3C6F870-DC46-4912-A8B9-D3D15A2F09F3Q36156347-FCE37DD4-777F-44CB-8431-12BCF09095B0Q36397581-F7A0665D-5398-47CC-8320-818825D315E6Q36446900-A2EEB6D0-A9FE-42A0-A3A2-40090E78D126Q36474557-1B3D2371-8227-417C-8F54-8EEACA7784FBQ36532471-A4AD95BD-E363-409D-9D45-9586FEB923EDQ36780136-94717C82-6E02-4035-A9F8-AFDE20D32F1AQ36909702-D46069FA-CCED-43AA-8138-DB16F3741404Q36943319-593E5B4C-6C55-4310-BC6B-8E83FE373F2AQ37103923-0B3CEBB6-7BBA-49C8-9E7B-4E382F9700A3Q37221660-45633887-038C-4111-82BA-248C9A84BAA4Q37304963-F9C9E8E1-BFF1-44AE-86E0-F794DED7E36AQ37309247-6DA050F9-E3CB-414E-AC68-78AD48C1E188Q37443937-A7788924-FA7A-4036-9636-DD00AC60B827
P2860
Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Phase I clinical trial safety ...... y HIV-1-uninfected volunteers.
@en
Phase I clinical trial safety ...... immunodeficiency virus type 1
@nl
type
label
Phase I clinical trial safety ...... y HIV-1-uninfected volunteers.
@en
Phase I clinical trial safety ...... immunodeficiency virus type 1
@nl
prefLabel
Phase I clinical trial safety ...... y HIV-1-uninfected volunteers.
@en
Phase I clinical trial safety ...... immunodeficiency virus type 1
@nl
P2093
P1433
P1476
Phase I clinical trial safety ...... y HIV-1-uninfected volunteers.
@en
P2093
Andrew J McMichael
Carol Smith
Christopher Conlon
Claudia Schmidt
Inese Cebere
Joanna E Roberts
Lucy Dorrell
Mary Brooks
Patricia E Fast
Sarah Rowland-Jones
P304
P356
10.1016/J.VACCINE.2005.08.041
P407
P577
2005-08-24T00:00:00Z